Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Launching of 2D Barcode Implementation on Pharmaceuticals Products and Starting the Pilot Phase in 2018

 
The Ministry of Public health has launched the pilot phase for 2D data Matrix Barcode Implementation on pharmaceutical products in the auditorium of the Ministry in Bir Hassan, under the patronage of Deputy Prime Minister Health Minister Ghassan Hasbani and in the presence of Director General of the Ministry Dr. Walid Ammar, the President of the Lebanese Order of Parmacists Georges Sili, the President of the Syndicate of Pharmaceutical Industries Caroline Abi Karam, the president of the Lebanese Pharmaceutical Importers Association Armond Phares, the President of the Syndicate of Hospital Owners Sleiman Haroun, the President of the Order of Physicians Raymond Sayegh, The Director of the Medical Care Directorate Dr. Joseph El-Helou, WHO representative Dr. Alissar Radi, Director of  E-Health program at the Ministry Lina Abou Mrad, and a number of representatives of hospitals and pharmaceutical industries.

The Director General Dr. Walid ammar explained the strategic frame of the project that comes within the Lebanese pharmaceutical sector reform and improvement plan. This project is achieved by reconsidering the legislations, regulating the registration and pricing of drugs, developing standards and programs to ensure quality in order to provide the patients with a safe quality-assured drug at the right price.

Mrs. Lina Abou Mrad then announced the launch of the implementation of 2D Barcode in 2018, while explaining the requirements of the information system that was lately developed to track the drugs across the supply chain, from manufacturing phase to sale to patients. Mrs Abou Mrad outlined as well the timeline for the implementation phase.

Hasbani

Hasbani said it was a pleasure to launch a new step for a long path of technology implementation to improve the performance of the healthcare sector. “Today we are launching the pilot phase for 2D barcode implementation that aims at ensuring the patient’s access to the safe drug, tracking drugs across the traceability supply chain, controlling illegal drugs and speeding up drugs recall from the Lebanese market and reimbursement of patients affiliated to insurers”, he added.
    ...
    133
    ...
ATC Name B/G Ingredients Dosage Form Price
L04AC05 USTEKIREL BioTech Ustekinumab - 90mg 90mg Injectable solution 94,672,508 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 400mg 400mg Injectable concentrated solution 75,875,312 L.L
L04AC05 STELARA BioTech Ustekinumab - 130mg 130mg Injectable concentrate for solution 235,593,517 L.L
L01FC01 DARZALEX BioTech Daratumumab - 400mg/20ml 400mg/20ml Injectable concentrate for solution L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable solution 49,744,595 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 80mg/4ml 80mg/4ml Injectable concentrated solution 11,127,864 L.L
L01FG01 BIVASTINA 400 BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 92,353,609 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 162mg/0.9ml 162mg/0.9ml Injectable solution 79,959,812 L.L
L01FG01 BIVASTINA 400 BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 53,111,763 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 200mg/10ml 200mg/10ml Injectable concentrated solution 25,485,937 L.L
B06AC05 TAKHZYRO BioTech Lanadelumab - 300mg/2ml 300mg Injectable solution 1,202,366,121 L.L
L01FG01 MVASI BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 58,035,926 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 400mg/20ml 400mg/20ml Injectable concentrated solution 47,925,322 L.L
B06AC05 TAKHZYRO BioTech Lanadelumab - 300mg/2ml Injectable solution 1,204,227,927 L.L
L01FG01 STIVANT BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 27,359,527 L.L
L04AC10 COSENTYX BioTech Secukinumab - 150mg/ml 150mg/ml Injectable solution 102,120,767 L.L
L01FG01 ZIRABEV BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable solution 49,965,229 L.L
L04AC13 TALTZ BioTech Ixekizumab - 80mg/ml 80mg/ml Injectable solution 85,080,792 L.L
L04AB04 HUMIRA BioTech Adalimumab - 40mg/0.4ml 40mg/0.4ml Injectable solution L.L
L01FG01 AVASTIN BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrated solution 24,533,456 L.L
L04AC16 TREMFYA BioTech Guselkumab - 100mg/ml 100mg/ml Injectable solution 190,195,151 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 100mg 100mg Injectable concentrated solution 24,533,456 L.L
L04AC16 TREMFYA BioTech Guselkumab - 100mg/ml 100mg/ml Injectable solution 190,195,151 L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable solution 14,719,570 L.L
L04AC18 SKYRIZI BioTech Risankizumab - 150mg 150mg Injectable solution 194,911,251 L.L
L01FG01 BIVASTINA 100 BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrate for solution 22,840,337 L.L
L01FG01 BIVASTINA 100 BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrate for solution 12,021,318 L.L
L01FG01 MVASI BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrate for solution 17,173,671 L.L
L01FG01 STIVANT BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrate for solution 14,719,570 L.L
B02BX06 HEMLIBRA BioTech Emicizumab - 30mg/ml 30mg/ml Injectable solution L.L
    ...
    133
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025